Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726903 · ClinicalTrials.gov registry record · Phase 4
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
A Phase 4 study of Gender Dysphoria, Adolescent, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05726903: Completed Phase 4 study of Gender Dysphoria, Adolescent, sponsored by University of Colorado, Denver.
NCT05726903 is a Phase 4 study of Gender Dysphoria, Adolescent that has completed, run by University of Colorado, Denver. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05726903, a Phase 4 study of Gender Dysphoria, Adolescent, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. The Investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for TGD youth. The Investigator will recruit transgender youth who are assigned female at birth, and currently or interested in using depo medroxyprogesterone (DMPA). Through focus groups and semi-structured interviews, the investigator hopes to guide providers in creating best practices and more equitable contraceptive counseling for TGD youth and measure satisfaction of DMPA in TGD youth.
Primary Outcome
Patient satisfaction with DMPA as assessed by thematic analysis of audio-recorded focus groups of each individual participant. Satisfaction will be measured through thematic analysis as the transcripts for the focus groups are coded, identifying phrases and words relating to satisfaction or dissatisfaction with their injection experience. Focus groups will be led by a member of the trans-masculine young adult community who will be trained on focus group procedures. Guides will be developed from
Conditions Studied
Interventions
- DRUG Depo-subQ Provera Injectable Product
Study Locations (1)
Colorado
- Comprehensive Women's Health Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 4 |
What the finished NCT05726903 record still lists
NCT05726903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Gender Dysphoria, Adolescent appearing as the primary indexed condition, and to 1 intervention - of which Depo-subQ Provera Injectable Product is the first listed.
NCT05726903 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05726903 about?
NCT05726903 is a clinical study titled "Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone". Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions tha...
What is the current status of trial NCT05726903?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2022-12-06. Estimated completion is 2023-11-17.
What conditions does trial NCT05726903 study?
This clinical trial studies the following conditions: Gender Dysphoria, Adolescent.
What interventions are being tested in trial NCT05726903?
The interventions under investigation include: Depo-subQ Provera Injectable Product (DRUG).
Who is sponsoring clinical trial NCT05726903?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726903 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05726903's enrollment target sits among peer trials
35 1506th of 2000 higher than 481 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI